Publication Date:
2011-11-18
Description:
Abstract 2729 Histone deacetylase inhibitors (HDACis) are among the most promising novel classes of anti-cancer compounds thanks to their ability of simultaneously targeting multiple pro-survival and anti-apoptotic pathways, while retaining a relatively good safety profile. Through the promotion of histone and non-histone protein acetylation, they can modulate not only expression and activation of key signaling proteins but also non-coding small RNAs (microRNAs) that post-transcriptionally control gene expression. Increasing evidence is pointing to an altered pattern of microRNA expression at the basis of the genesis and the maintenance of lymphoid malignancies and in particular Burkitt's lymphoma (BL). To better elucidate the mechanism accounting for the potent anti-lymphoma activity of the new-generation pan-HDACi ITF2357 (Givinostat®, Italfarmaco S.p.A.), we studied its ability to modulate the microRNA expression profile in human BL cell lines. We performed microRNA expression profiling of Raji cells exposed to 200 nM ITF2357 for 24, 48, 72 hours or untreated. At any time points, we found an average of 6 and 4 microRNAs that displayed a more than 1.8 fold increase and decrease respectively (p
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink